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ABSTRACT: Purpose of the study: Osteonecrosis of the hip mostly affects young individuals and often
progresses to a debilitating disease. Several treatment modalities exist, but none are completely
satisfactory. This study evaluates the clinical outcome of patients treated with core decompression and
insertion of a porous tantalum implant in the femoral head. This procedure is similar to commonly
performed procedures, but has the additional advantages of providing structural support to the
necrotic femoral head while having no donor-site morbidity. Methods: We evaluated 15 patients with
18 osteonecrotic hips with Steinberg stage III (3 hips) and IV (15 hips) disease. The mean age of the
patients was 42 years-old (eldest 66), and the mean time for follow-up was 23 months. The outcome
measure was hip function, evaluated with the Harris hip score, and the end point was total hip
arthroplasty, or referral for this procedure. Results: The success rate at twelve months postoperatively
was 77.8%, and the overall success rate was 44.5%. Failures occurred at a mean time of 11.7 months,
and one complication, a periprosthetic fracture, occurred 4 months postoperatively. On average,
patients who did well improved their Harris hip scores by 21.7 points, and patients who eventually
required arthroplasty decreased their scores by 14 points. Conlusions: Core decompression with porous
tantalum implants showed encouraging success rates and early clinical results in patients with
advanced stage osteonecrosis, but further larger scale studies are required to identify the population
best suited for this procedure.    
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INTRODUCTION
Osteonecrosis of the hip, previously named avascular
necrosis, is a naturally progressive disease typically
affecting young individuals (the mean age
approximately 35 years old) (1). It occurs when blood
supply to the femoral head is disrupted, resulting in
infarction and avascular necrosis of bone. Several
etiologies have been identified, such as trauma
(femoral neck fracture or posterior hip dislocation),
blood disorders (e.g. sickle cell anemia), and radiation
therapy (2, 3, 4). Other important risk factors identified
are the use of alcohol, use of corticosteroids (e.g. in
patients with systemic lupus erythematosus, or status-
post renal transplant) and cigarette smoking, as well as
pregnancy (5, 6). Having HIV has also been associated
with an increased incidence of osteonecrosis of the
femoral head, but it is unclear whether this is related to
the virus or to the antiviral therapy (7). Much is still to
be learned about the etiologies and the pathophysiology
of this disease.
When left untreated, 80% of clinically diagnosed
cases of femoral head osteonecrosis will progress, most
often incapacitating the patient due to pain and decrease
in hip mobility (8). The natural history of this condition
is that it is usually initially confined to the superiorOutcome of a Porous Tantalum Implant for  Osteonecrosis  5 Vol. 10  No. 1
weight-bearing portion of the femoral head, but
progresses, rendering the area susceptible to collapse,
and leading to subchondral fractures. Eventually,
degenerative changes of the hip joint ensue (9). In the
United States, the estimated incidence of this condition
is 10,000-30,000 per year, and 5-12% of all total hip
arthroplasties are performed to treat patients with
osteonecrotic hips. This latter treatment modality was
proven to be highly successful (3). However, it is not
appealing to the young and active patient population
often affected by osteonecrosis of the hip, as they will
most likely outlive their prosthesis and require revision.
Non-operative treatment modalities also exist. They are
divided into external biophysical modalities
(extracorporeal shock-wave therapy, hyperbaric
oxygen, or pulsed electromagnetic field) and
pharmacological therapies (lipid-lowering agents,
anticoagulants, or bisphosphonates). Mont MA et al.
did a complete review of the English literature from
1960 to 1993 and found 21 studies where clinical
outcomes of osteonecrotic hips treated non-operatively
(excluding electrical stimulation) were evaluated (3).
Together, these studies yielded an overall clinical
success rate 22.7%. Pulsed electromagnetic field has
been proven to result in clinical improvement and
stabilization of osteonecrosis on radiographs by two
studies done in the late 1980s, but this modality has
never gained popularity (10, 11). Also, new
pharmacological measures as well as the use of growth
and differentiation factors have shown potential in
preventing and treating this disease, but clinical
research projects are still awaiting long-term follow-up
results to provide recommendations (4).
Joint-preserving surgical procedures are presently the
most commonly used approach to treatment of
osteonecrotic hips. They are described as temporizing
measures, possibly preserving these femoral heads.
Most have shown superiority over symptomatic
treatment, but none are completely satisfactory. The
two most common procedures are core decompression
and fibular bone-grafting techniques. Core
decompression alone has the disadvantage of lacking
subchondral support, whereas fibular grafting
techniques have increased morbidity associated with
graft harvest, longer operative time and blood loss, as
well as rehabilitative complications (3, 12, 13). The
rationale for fibular bone-grafting is that it allows
decompression of the femoral head as well as the
removal of necrotic bone with its replacement by the
graft. This graft plays the important role of providing
structural support and scaffolding, facilitating repair
and remodeling of subchondral bone (14, 15).
Since the main disadvantages of fibular grafting
techniques are related to the bone-graft harvesting, the
use of another material with characteristics similar to
bone graft presents an interesting modality. Porous
tantalum is an expanded (foam-like) metal currently
being used in several orthopedic procedures, namely
hip and knee arthroplasty, spine surgery, and as bone
graft substitute. It was found to have an excellent
biocompatibility and to be safe to use in vivo (16). It has
a high volumetric porosity and is corrosion resistant. Its
modular elasticity is similar to that of subchondral
bone, yet its strength, fatigue properties, endurance
limits, and initial stability against bone are all superior
to natural bone grafts (17,18,19). In fact, a recent study
done in animal models showed that it had rapid tissue
ingrowth and fixation strength, which allows faster
return to full weight-bearing compared to procedures
using fibular bone graft (20). Furthermore, another
study which mechanically tested porous tantalum
implants in a model mimicking a necrotic femoral head,
demonstrated that tantalum implants reduced
subchondral plate deflection and that its strength was
9.3 times greater than the maximum force it sustains
when placed in the femoral head (21). Finally, local
foreign body infection is a possible complication of
orthopedic implants, and in this regard, Schildhauer et
al. have studied the adhesion of the two bacteria that are
of most concern:  Staphylococcus aureus and
Staphyloccocus epidermis (22). The former was found
to adhere significantly less (p<0.05) to pure tantalum
compared to titanium alloy, polished stainless steel, and
tantalum-coated stainless steel, and the latter bacteria
adhered to pure tantalum to an extend similar to other
materials used in orthopedics. All of these properties
make tantalum implants good substitutes for fibular
bone grafts in decompressing surgeries for
osteonecrosis of the hip. Theoretically, porous tantalum
implants have the advantages of fibular grafts,
providing core decompression and structural support,
and, in addition, they represent a minimally invasive
procedure with no donor-site morbidity. They thus have
the theoretical potential of limiting the progression of
the disease, which could delay, and maybe even
prevent, the need for a hip replacement. This clinical
study was performed to verify this theoretical
advantage of the tantalum plug relative to core
decompression alone or to fibular bone-grafting
techniques.
This study evaluates the early clinical outcomes of
patients with advanced osteonecrotic femoral heads
(presenting with subchondral collapse or femoral head
flattening) treated with insertion of porous tantalum
implants. We expected that this procedure would
improve patients' clinical symptoms, most often being
pain and limitations in hip function, and, in turn, delay
the need for revision with total hip arthroplasty, which
was the endpoint of our study.6 McGill Journal of Medicine 2007
METHODS
This prospective study was conducted at the Montreal
General Hospital, from April 2002 to February 2004.
Experimental subjects were taken from patients
referred to a single surgeon for treatment of Steinberg
Stage III and IV (Table 1) unilateral or bilateral femoral
head osteonecrosis. Only patients with non-traumatic
etiologies for the disease were considered for
participation in the study. Exclusion criteria also
included patients who were actively being treated with
corticosteroids, had previous surgery to the affected
hip, or were unwilling to have surgery at time of
clinical presentation. Patients were offered the tantalum
implant procedure when they were unwilling to have
treatment with free vascularized fibular graft or total
hip arthroplasty. 19 patients with 22 osteonecrotic hips
treated with tantalum implants were initially entered in
the study and signed an informed consent form prior to
enrollment. Four patients were removed from the study
as they were unavailable for follow-up at one year or
later. One patient sustained trauma, more precisely a
fall from her own height, resulting in a periprosthetic
fracture one month postoperatively. This patient was
not included in data analysis, but was rather included in
the results as a complication. Thus, functional
outcomes of 14 patients with 17 osteonecrotic hips
were used for analysis. The average age of the patients
was 42 years old (range 19 to 66). Table 2 outlines
details on patient demographics. 
All patients underwent the same operative procedure
through a minimally invasive lateral approach (2-3 cm
skin incision).  First, a core decompression technique
was done under c-arm fluoroscopy imaging. It
consisted of inserting a guide pin from the lateral
femoral cortex into the femoral head and using a core
reamer over this guide pin to create a 10-mm diameter
bone channel. A porous tantalum plug (Zimmer
Trabecular Metal Technology, Trabecular Metal
Osteonecrosis Intervention Implant System, Warsaw,
Indiana; see Figure 1), was then inserted in this bony
channel. This implant is fully made of pure porous
tantalum, with an interconnected porosity of 75-80%. It
has a cylindrical shape of 10 mm in diameter, and
comes in lengths of 70 to 130 mm, available in 5 mm
increments. The implant is threaded on a 25 mm length
at one end, where the diameter is 14 mm, and a
hemispherical tip at the other, for support of the
subchondral plate (see Figure 2). Bilateral procedures
were performed in the same operative period, whether
they were both tantalum implants or one tantalum
implant and one free vascularized fibular graft, except
for one patient who had a tantalum implant inserted in
each hip at 3-month interval. Postoperative care
consisted of prophylactic intravenous antibiotic
(Cefazolin 1-2 g IV q8h twice) and anticoagulation
therapy (Low Molecular Weight Heparin 5000 IU SC
qd until weight bearing). Patients were instructed to be
Stage Criteria
0 Normal or nondiagnostic radiograph, bone scan, MRI
I Normal radiographs; abnormal bone scan and/or MRI
A–Mild (<15% of femoral head affected)
B–Moderate (15%–30%)
C–Severe (> 30%)
II Cystic and sclerotic changes in femoral head
A–Mild (<15% of femoral head affected)
B–Moderate (15%–30%)
C–Severe (>30%)
III Subchondral collapse (crescent sign) without flattening
A–Mild (<15% of articular surface)
B–Moderate (15%–30%)
C–Severe (>30%)
IV Flattening of femoral head
A–Mild (<15% of surface and < 2 mm 
depression)
B–Moderate (15%–30% of surface and 2–4 
mm depression)
C–Severe (>30% of surface and > 4 mm 
depression)
V Joint narrowing or acetabular changes
A–Mild*
B–Moderate*
C–Severe*
VI Advanced degenerative changes
*Average femoral head and estimated acetabular involvement.
Table 1. Steinberg stages of osteonecrosis of the hip (30)
Gender:
Males
Females
No of patients
6
8
Race:
Caucasian
African-American
Asian
11
2
1
Etiology:
Idiopathic
Corticosteroids
Alcohol induced
Sickle cell anemia
Chemotherapy
Radiation therapy
HIV
Pregancy induced
No of hips
4
3
4*
1
1
1
2*
1
Extent & treatment of ON: 
Unilateral disease
Bilateral disease treated with:
bilateral TI
TI and FVFG
TI and no surgical treatment
5
3
3
3
Steinberg Stage:
III
IV
3
14
* Hips of patients with bilateral ON and TI
ON= Osteonecrosis; LTI= Tantalum implant;FVFG= Free   
vascularized fibular graft
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non-weight-bearing for 3 weeks, to partial weight-bear
for the next 3 weeks, and to weight bear as tolerated
thereafter.
The primary outcome of this study was functional
improvement, which was assessed with the Harris hip
score. This 15-question scoring tool for rating hip
function was formulated and published in 1969 by WH
Harris, for evaluation of traumatic arthritis of the hip,
and is now the scoring tool the most commonly used
worldwide for assessment of hip function in general
(23). It consists of a point scale of a maximum of 100
points subdivided into 4 subscales: pain (44 points),
function (47 points), range of motion (5 points),
absence of deformity (4 points). A total Harris hip score
below 70 points is considered a poor result, 70 to 80
fair, 80 to 90 good, and 90 to 100 excellent (24).
Söderman and Malchau performed a validity and
reliability test for the Harris hip score (24). They found
that test and retest reliability between two examinations
by physicians had correlation coefficients of 0.94, and
concluded that this scoring system had high content and
construct validity. This score was obtained for each
subject at their pre- and post-operative visits. Because
functional improvement after orthopedic surgeries
usually improve mostly throughout the first year
following the procedure and plateaus thereafter, post-
operative scores obtained at 12 months or later were
used as data points for analysis. When more than one
follow-up with Harris hip score recording had been
done at one year post-operatively or later, the best score
was taken, which was always the latest one. Paired T-
tests were used to compare pre-operative and post-
operative Harris hip scores among all patients, as well
as within subgroups of patients who eventually failed
and those who did not. Failure, defined as being
referred for or undergoing a total hip arthroplasty was
the end point of this study. Survival rate was calculated
with the Kaplan-Meier Method and refers to patients'
hips which did not progress to the point of requiring
further surgical treatment. These analyses were
performed with SSPS Manager (version 11.5; SSPS
Inc, Chicago, Illinois). Significance was set at p<0.05.
RESULTS
Outcome at 12 months or more
Paired t-test analysis was done to compare pre-
operative to post-operative Harris hip scores of patients'
hips that had not failed at 12 months post-operatively
(Refer to Table 3). There were 14 such hips in 12
patients. 2 patients with unilateral treatment were
removed for analysis of hip function improvement
since no pre-operative scores had been obtained. Of the
12 hips of 10 patients remaining, 8 hips (75%) in 7
patients improved their Harris hip scores, the mean
improvement was of a magnitude of only 3.8 points.
Standard deviations for the mean postoperative score
and score improvement were very large, which reflects
the discrepancy in individual postoperative values.
When looking closely at these, it is noticed that they
were very low in patients whose hips eventually failed,
whereas they were greatly increased in patients whose
tantalum implants succeeded, preventing the need for
joint replacement surgery before the end of the study.
Mean Harris hip score improvement was thus
calculated separately for failed and non-failed tantalum
implant procedures: a 21.7-point increase was obtained
for patients who did well, compared with a mean
decrease of 14.0 points for patients whose implants
failed. This excludes three patients in whom three hips
failed prior to the 12-month mark, and whose pre-
operative Harris hip scores were particularly low
(average 27.6 points).
Failures
The average time of final follow-up and recording of
Figure 1.Trabecular Metal Osteonecrosis Intervention Implant
System; tantalum implant used in all patients of this study. 
Retrieved from http://www.zimmer.com
Figure 2. Porous tantalum implant in a Steinberg stage IV
osteonecrotic hip, 2 years post-operatively.
Mean Harris hip scores (points)
No of
hips 
Pre-op ± SD Post-op ±
SD
Improvement ±
SD
P-value
All hips 12
14*
56.1 ± 9.4 59.9 ± 25.6
63,9 ± 25.9
3.8 ± 23.8 0.590
Non-failed
hips
6
8*
59.5 ± 9.7 81.2 ± 10.0
82.9 ± 10.2
21.7 ± 15.0 0.017
Failed hips:
at any time
>12 mo
<12mo
9
6
3
44.3 ± 16.0
52.6 ± 8.6
27.6 ± 14.4
38.6 ± 16.0 (-)14.0 +/- 15.9 0.083
Table 3. Pre and post operative (?12 months) Harris hip scores
*includes two hips for which no preoperative Harris hip score was
recorded8 McGill Journal of Medicine 2007
the 14 Harris hip scores used for analysis was 23.2
months (range 12 to 48). This excludes three patients,
one of which had bilateral involvement, in whom one
operated hip failed prior to the 12-month mark, more
precisely at 7, 8 and 10 months post-tantalum insertion,
as well as one patient who sustained mild trauma to her
single operated hip (fall from own height) resulting in a
periprosthetic fracture (see Figure 3). This represents a
failure rate of 22.2% at one year postoperatively. 6
additional hips in 4 patients, including all 3 patients
with bilateral implant intervention including one whose
contralateral hip had failed earlier, had undergone total
hip arthroplasty before the final time of follow-up.
Therefore, 10 out of 18 (55.6%) tantalum implant
procedures failed within the study period. The mean
time for failure, excluding the patient with a
periprosthetic hip fracture, was 11.7 months (SD=3.7,
range 7 to 20 months), and the mean age at surgery of
the patients who failed was 50.1 years old (SD=12.1,
range 29 to 66), compared to a mean age of 36.8 years
old (SD=12.2, range 19 to 55) for the patients whose
tantalum implant did not fail. Refer to Figure 4 for the
Kaplan-Meier survivorship curve.
DISCUSSION
Osteonecrosis of the femoral head is a debilitating
disease that requires treatment. Since the late 1960s,
several studies have evaluated effectiveness of potential
techniques to treat this condition, such as core
decompression, vascularized and nonvascularized
fibular bone grafts, and angular or rotational
osteotomies. Mont et al. performed a meta-analysis to
look at the these studies, which were almost all
performed on precollapse (Steinberg Stage I or II)
osteonecrotic femoral heads and thus their results
cannot be compared to ours (3). Furthermore, the
conclusion of the meta-analysis was that early
diagnosis and intervention prior to collapse of the
femoral head, thus in earlier stages than in our patient
population, is key to a successful outcome of joint-
preserving procedures. However, 3 of the studies they
looked at evaluated Steinberg Stage IV osteonecrotic
hips treated with vascularized fibular bone grafts; they
showed clinical success rates of 52, 48 and 71% at
mean follow-up times of 12 months or more (25, 26,
27). Mont et al. concluded in their meta-analysis that
for femoral heads that have already collapsed, such as
in our patients' hips, the results of joint-preserving
procedures are less satisfactory than the results of total
hip arthroplasty (4).
In the present study, the success rate, defined as not
requiring further hip treatment after core
decompression tantalum implant insertion, was 77.8%
at twelve months postoperatively. The overall success
rate at final time of follow-up (mean of 23.2 months)
was 44.5%. Failures (10 hips, 55.6%) occurred at a
mean time of 11.7 months. One complication occurred:
a periprosthetic fracture at four months postoperatively.
This patient was included in the failure rate, as further
surgical hip treatment was done, but was not included
in the mean failure time, as this failure was due
primarily to trauma, and thus does not reflect the time
of failure of the tantalum implant per say. Patients who
did not require further treatment within the follow-up
time improved their Harris hip scores by 21.7 points,
and patients who eventually underwent arthroplastic
treatment decreased their score by 14 points, on
average. The mean age at tantalum implant insertion in
patients who failed was 50.1 years old, compared to
36.8 in patients who did well. This 13.4 years of age
difference is statistically significant (p=0.040). The
average preoperative Harris hip score of patients who
failed was 44.3, compared with 59.5 for patients who
did well. This represents a 15.2-point difference, which
is also statistically significant (p=0.039). This suggests
that age at surgery and preoperative hip function have
prognostic implications for the porous tantalum implant
insertion: the younger, less symptomatic, and less
debilitated patients had the most favorable outcomes.
Figure 3.
Periprosthetic fracture
occurring 4 weeks
post-porous tantalum
implant insertion after
a fall from her own
height. 
Figure 4. Kaplan-Meier survivorship curve, with conversion to
total hip replacement or referral for this procedure, as the end
point. Censored patients are ones who did not reach the end
point before their final follow-up time. Outcome of a Porous Tantalum Implant for  Osteonecrosis 9 Vol. 10  No. 1
Our patient population is not large enough to make an
association between outcome and etiology or uni/bi-
lateralism of the disease process. Our statistical
findings are also limited in power because of the small
number of subjects. The follow-ups, and thus
postoperative score recording, were not done at the
same time interval with respect to the surgery, making
the results not as reproducible and precise as they could
have been.
Tsao et al performed the only other published study to
date evaluating the clinical outcome of porous tantalum
implants in osteonecrotic human hips (28). They
evaluated 113 hips treated with tantalum implants.
Intraoperative classification yielded 7 and 12 hips of
Steinberg Stage III and IV respectively. The mean
Harris hip scores of hips improved by 26 and 9 points
in patients with stage III and IV osteonecrotic hips
respectively. This is comparable to our 21.7-point
average improvement in our patients'  hips. One (14%)
stage III and three (25%) stage IV were revised, which
is similar to our failure rate of 22.2% at one year. Their
success rate for all stage II disease, which represented
the bulk of their experimental data, was 85.3% at
twelve months. They concluded that treatment of early
stage osteonecrosis of the femoral head with core
decompression and a porous tantalum implant show
encouraging success rates, especially in association
with early stage disease.
Veillette et al. have also recently done a study, with a
publication in press, assessing clinical and radiographic
outcomes of osteonecrotic hips treated with core
decompression and porous tantalum implant (28). They
evaluated 60 hips: 1 Steinberg stage I, 49 stage II, and
8 stage III. They used the same hip function evaluation
tool and end point as we did. Their one-year survival
rate was 91.8% at one year. This is higher than ours, but
it is likely due to the fact that most of their hips had
stage II osteonecrosis, compared to a majority of stage
IVs in our study. Overall, 3 of their 8 hips with stage III
disease were converted, representing a success rate of
only 62.5%, which is more similar to our results. They
concluded that treatment of early stage osteonecrosis of
the femoral head with core decompression and a porous
tantalum implant show encouraging success rates,
especially in patients with early stage disease. 
In conclusion, core decompression with porous
tantalum implant insertion provides a minimally
invasive surgical treatment option to treat advanced
osteonecrotic hips, with clinical outcomes and success
rates comparable to other commonly used surgical
procedures. It has the advantage of providing structural
support without having associated donor-site morbidity.
It seems however that this treatment modality is more
successful in younger patients with more functional and
less symptomatic hips. This is fortunate as it is for
younger patients that the only definitive treatment so
far, total hip replacement, is least appealing, as they are
likely to outlive a hip prosthesis, thus requiring one or
more revisions. In further studies, it would be useful to
perform larger studies, perhaps at a multicenter level, to
clearly elucidate the association between pre-operative
stage and etiology of the disease, as well as patients' age
with success rate. This would enable us to make clear
recommendations for choosing the best treatment
modality for the individual patient.
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